HomeCompareCLBS vs PEP

CLBS vs PEP: Dividend Comparison 2026

CLBS yields 131.33% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBS wins by $12.85M in total portfolio value
10 years
CLBS
CLBS
● Live price
131.33%
Share price
$0.43
Annual div
$0.56
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.99M
Annual income
$5,201,713.69
Full CLBS calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — CLBS vs PEP

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBSPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBS + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLBS pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS
Annual income on $10K today (after 15% tax)
$11,163.23/yr
After 10yr DRIP, annual income (after tax)
$4,421,456.64/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, CLBS beats the other by $4,368,862.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + PEP for your $10,000?

CLBS: 50%PEP: 50%
100% PEP50/50100% CLBS
Portfolio after 10yr
$6.57M
Annual income
$2,631,794.68/yr
Blended yield
40.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

CLBS
No analyst data
Altman Z
-42.9
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys
0
PEP buys
0
No recent congressional trades found for CLBS or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBSPEP
Forward yield131.33%3.63%
Annual dividend / share$0.56$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$12.99M$141.9K
Annual income after 10y$5,201,713.69$61,875.67
Total dividends collected$11.90M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CLBS vs PEP ($10,000, DRIP)

YearCLBS PortfolioCLBS Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$23,833$13,133.21$10,849$509.42+$13.0KCLBS
2$54,754$29,252.94$11,969$750.47+$42.8KCLBS
3$121,396$62,809.15$13,500$1,124.14+$107.9KCLBS
4$260,039$130,144.39$15,680$1,721.66+$244.4KCLBS
5$538,781$260,539.45$18,929$2,715.34+$519.9KCLBS
6$1,080,999$504,503.28$24,023$4,450.80+$1.06MCLBS
7$2,102,673$946,004.75$32,510$7,669.92+$2.07MCLBS
8$3,969,574$1,719,713.85$47,709$14,093.60+$3.92MCLBS
9$7,281,647$3,034,202.37$77,415$28,083.48+$7.20MCLBS
10$12,993,076$5,201,713.69$141,922$61,875.67+$12.85MCLBS

CLBS vs PEP: Complete Analysis 2026

CLBSStock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this CLBS vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHDCLBS vs JEPICLBS vs OCLBS vs KOCLBS vs MAINCLBS vs MOCLBS vs PMCLBS vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.